Related Experiment Video

Updated: Aug 8, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Inhibition of gastric cancer-associated angiogenesis by antisense COX-2 transfectants

Yuan-Gen Fu1, Joseph Jy Sung, Kai-Chun Wu

  • 1Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital 30-32 Ngan Shing Street, Shatin N.T., Hong Kong, SAR, China.

Cancer Letters
|May 26, 2005
PubMed

Insights

Selective inhibition of cyclooxygenase-2 (COX-2) suppresses gastric cancer angiogenesis. Targeting COX-2 alone reduces cancer cell proliferation, migration, and blood vessel formation, offering a potential therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Angiogenesis is crucial for gastric cancer growth and metastasis.
  • Cyclooxygenase-2 (COX-2) is implicated in tumor angiogenesis.
  • Selective COX-2 inhibition is a potential anti-cancer strategy.

Purpose of the Study:

  • To investigate the effects of selective COX-2 inhibition on angiogenesis in the SGC7901 gastric cancer cell line.
  • To evaluate the impact of COX-2 inhibition on endothelial cell function and in vivo angiogenesis.

Main Methods:

  • Stable transfection of antisense COX-2 cDNA (COX-2-AS) in SGC7901 cells.
  • Pharmacological inhibition using a selective COX-2 inhibitor (NS398).
  • Assessing effects on human umbilical vein endothelial cell (HUVEC) proliferation, migration, and tube formation.
  • Evaluating in vivo angiogenesis models.

Main Results:

  • Conditioned media from treated SGC7901 cells suppressed HUVEC proliferation, migration, and tube formation.
  • Both COX-2-AS and NS398 treatments inhibited in vivo angiogenesis.
  • The inhibitory effects were partially reversed by prostaglandin E2 (PGE2) addition.

Conclusions:

  • Selective COX-2 inhibition significantly impairs gastric cancer-associated angiogenesis.
  • COX-2 plays a critical role in promoting angiogenesis in gastric cancer.
  • Targeting COX-2 alone may be a viable therapeutic approach for gastric cancer.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Combined Conditional Knockdown and Adapted Sphere Formation Assay to Study a Stemness-Associated Gene of Patient-derived Gastric Cancer Stem Cells09:24

Combined Conditional Knockdown and Adapted Sphere Formation Assay to Study a Stemness-Associated Gene of Patient-derived Gastric Cancer Stem Cells

Published on: May 9, 2020

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...